METHODS: A systematic literature search was performed on MEDLINE (PubMed), Embase, Scopus, and Cochrane Library for published literature; studies comparing the outcome of UC-II supplementation with placebo/control in adult humans with early knee OA were included. The outcomes evaluated were VAS Score, quality of life - Western Ontario and McMaster Universities (WOMAC-score), Knee function, Knee range of motion, and any complications during the course of treatment.
RESULTS: A total of 293 results were obtained after a primary search; 8 randomized control trials (RCT) were finally included. A total of 243 patients received UC-II supplementation (91 men and 152 women). The overall mean age range for the intervention group was 53.5±0.99 to 68.7±5.3 years across all included studies, and the mean follow-up duration was 3 to 6 months. Outcome measures like WOMAC and VAS scores showed better outcomes with UC-II in comparison to placebo. Walking measurements improved significantly from the baseline, reflected in improved timed up-and-go and 6-minute walk tests (6MWT). The overall complications were similar to other supplements.
CONCLUSIONS: With limited literature, UC-II has shown promise as a potent supplement in early knee OA with good pain relief and improved function. However, further large-scale studies are needed to substantiate these findings.
方法:在MEDLINE(PubMed)上进行了系统的文献检索,Embase,Scopus,和Cochrane图书馆的已发表文献;包括比较UC-II补充与安慰剂/对照在成人早期膝关节OA中的结果的研究。评估的结果是VAS评分,生活质量-西安大略省和麦克马斯特大学(WOMAC分数),膝关节功能,膝关节运动范围,以及治疗过程中的任何并发症。
结果:经过初步搜索,共获得293个结果;最终纳入8个随机对照试验(RCT)。共有243名患者接受UC-II补充(男性91名,女性152名)。在所有纳入研究中,干预组的总体平均年龄为53.5±0.99至68.7±5.3岁,平均随访时间为3~6个月。与安慰剂相比,UC-II的WOMAC和VAS评分等结果指标显示出更好的结果。步行测量值从基线显着改善,反映在改进的定时上行和上行和6分钟步行测试(6MWT)。总体并发症与其他补充剂相似。
结论:由于文献有限,UC-II已显示出有望作为早期膝关节OA的有效补充,具有良好的疼痛缓解和改善的功能。然而,需要进一步的大规模研究来证实这些发现.